Natera stock pre-market at EUR 358.70: plus 0.82 percent
Published on 10/07/2026 at 08:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Natera stock was at EUR 358.70 pre-market at 8:11 a.m. CEST on October 7, 2026, up 0.82 percent versus the EUR 355.80 Lang & Schwarz close from October 6, 2026.
Pre-market price
The Lang & Schwarz quote puts Natera stock at EUR 358.70 before the Xetra open, with the previous close at EUR 355.80. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Natera stock.
Previous session
The October 6, 2026, Lang & Schwarz closing price was EUR 355.80. The current pre-market quote is stated separately from the company announcement dated October 6, 2026.
Signatera data presented at ASTRO
Natera said new Signatera data were presented at the 2026 annual meeting of the American Society for Radiation Oncology. According to the BioSpace-published release, four oral presentations covered gastrointestinal and gynecologic cancers and examined Signatera’s use in treatment-response monitoring and risk stratification.
The release described a study in locally advanced rectal cancer in which Signatera identified every instance of local cancer growth or recurrence, with 100 percent sensitivity and 97 percent specificity after neoadjuvant treatment. In an anal squamous cell carcinoma study, 18-month progression-free survival was 8 percent after a positive result and 97 percent among patients who remained negative after chemoradiation.
